OpenURL Connection Search

Select item for more details and to access through your institution.

Janus kinase inhibitors for the treatment of atopic dermatitis: Real‐life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 11, p. e1307, doi. 10.1111/jdv.19302
By:
- Reguiai, Z.;
- Becherel, P. A.;
- Fougerousse, A. C.;
- Chaby, G.;
- Perrot, J. L.;
- Begon, E.;
- Jacobzone‐Lévêque, C.;
- Boulard, C.;
- Badaoui, A.;
- Poreaux, C.;
- David, L.;
- Quiles‐Tsimaratos, N.;
- Lons‐Danic, D.;
- Fite, C.;
- Liegeon, A.‐L.;
- Patchinsky, A.;
- Parier, J.;
- Garcia, C.;
- Estève, E.;
- Mohty, R.
Publication type:
Article
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2020, v. 34, n. 11, p. e676, doi. 10.1111/jdv.16761
By:
- Fougerousse, A.‐C.;
- Perrussel, M.;
- Bécherel, P.‐A.;
- Begon, E.;
- Pallure, V.;
- Zaraa, I.;
- Chaby, G.;
- Parier, J.;
- Kemula, M.;
- Mery‐Bossard, L.;
- Poreaux, C.;
- Taieb, C.;
- Maccari, F.;
- Reguiai, Z.
Publication type:
Article
Bullous drug eruption to Nigella sativa oil: Consideration of the use of a herbal medicine - clinical report and review of the literature.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2017, v. 31, n. 4, p. e217, doi. 10.1111/jdv.13982
By:
- Bonhomme, A.;
- Poreaux, C.;
- Jouen, F.;
- Schmutz, J. ‐ l.;
- Gillet, P.;
- Barbaud, A.
Publication type:
Article
Managing generalized interferon-induced eruptions and the effectiveness of desensitization.
Published in:
Clinical & Experimental Allergy, 2014, v. 44, n. 5, p. 756, doi. 10.1111/cea.12217
By:
- Poreaux, C.;
- Bronowicki, J.‐P.;
- Debouverie, M.;
- Schmutz, J.‐L.;
- Waton, J.;
- Barbaud, A.
Publication type:
Article

Found: 4

Janus kinase inhibitors for the treatment of atopic dermatitis: Real‐life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19.

Bullous drug eruption to Nigella sativa oil: Consideration of the use of a herbal medicine - clinical report and review of the literature.

Managing generalized interferon-induced eruptions and the effectiveness of desensitization.